AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARE

Amarin to Present at H.C. Wainwright’s 24th Annual Global Investment Conference

30 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

28 Aug 2022 04:51:07 By Nasdaq GlobeNewswire

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes

26 Aug 2022 07:19:00 By Nasdaq GlobeNewswire

Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress

15 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update

03 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022

20 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales

13 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo

30 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Amarin Receives Positive Recommendation from United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)

10 Jun 2022 05:00:00 By Nasdaq GlobeNewswire

Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business

06 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Amarin Appoints Tom Reilly as New Chief Financial Officer

06 Jun 2022 07:15:00 By Nasdaq GlobeNewswire

Amarin Announces Appointment of New Directors and Board Leadership Changes

19 May 2022 07:23:13 By Nasdaq GlobeNewswire

Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs

16 May 2022 07:00:01 By Nasdaq GlobeNewswire

Amarin to Present at Two Upcoming Investor Conferences

12 May 2022 07:00:01 By Nasdaq GlobeNewswire

Amarin Reports First Quarter 2022 Financial Results and Provides Business Update

04 May 2022 06:00:01 By Nasdaq GlobeNewswire

New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction (Heart Attack)

03 May 2022 07:00:02 By Nasdaq GlobeNewswire

Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl)

26 Apr 2022 07:49:33 By Nasdaq GlobeNewswire

Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022

19 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes

01 Apr 2022 06:00:00 By Nasdaq GlobeNewswire

Amarin Receives Reimbursement for VAZKEPA® in Sweden

28 Mar 2022 06:00:00 By Nasdaq GlobeNewswire